Essilor International, the French ophthalmic optics company that designs, manufactures and distributes lenses, was fined by the French Competition Authority (FCA). The company will have to shell out €81 million to settle the penalty with the antitrust regulators in France.
According to Reuters, the FCA handed down its decision to Essilor for alleged unfair business practices. The competition watchdog said that the fine was for the violations that stretch over 11 years.
The authorities explained this week that optic lens maker’s actions had been mapped out to impede the development of online sales for corrective lenses in France. EssilorLuxottica, Essilor’s parent company, will pay €15 million out of the total penalty of €81 million.
The Autorite de la Concurrence said EssilorLuxottica and its Essilor International engaged in practices that blocked online sales of some prescription lenses in the country. The antitrust regulator determined that Essilor abused its dominant position in the lenses distribution market this move has become an obstruction in the growth of online sales of other eye-corrective lens and eyeglasses firms such as DirectOptic, Sensee, and Happyview.
Market Watch reported that as early as 2009, Essilor prevented some online platforms from selling its Essilor or Varilux optic lenses to customers. The authorities added the company refused to deliver its branded lenses as well while also barring the websites from displaying the Essilor logo and trademark. This practice continued for more than a decade, which is why the FCA imposed a hefty fine.
Meanwhile, in a press release, EssilorLuxottica said it is challenging the decision of the FCA. The revealed its intention to file an appeal as it strongly disagrees with the regulators’ decision.
“EssilorLuxottica acknowledges that the French competition authority (FCA) has published today a decision concerning Essilor International,” the French-Italian Ray-Ban manufacturer said. “EssilorLuxottica firmly believes in the legality of its practices and in the relevancy of distributing specific segments of prescription products under conditions that enable us to ensure that consumers can get the best vision correction that is required by their individual vision needs.”
EssilorLuxottica further reiterated that its business practices were fully compliant with the competitive and regulatory conditions in the mentioned period. For its appeal, the firm is confident that it will be able to prove that the FCA’s decision is groundless.


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



